Low-dose-rate prostate brachytherapy: 4–8 week postimplant prostate-specific antigen a novel predictor of biochemical failure-free survival

Callaghan, Cameron; Wang, Lin; Alluri, Abhishek; Lauve, Andrew; Boyer, Cynthia; Russell, William E.

doi:10.1016/j.brachy.2017.07.016

Cited by 4 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies have reported the significantly worse biochemical outcomes of PI for younger patients (9,30,31). Others have reported that age was not associated with biochemical failure in low-risk patients (30,32,33,34,35). The relationship between younger age and more aggressive clinical behavior of PCa has been previously documented (36), and there is evidence that young-age PCa has several biological and genetic features, distinct from elderly-onset PCa (37).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Biochemical outcomes and predictive factors by risk group after permanent iodine-125 seed implantation: Prospective cohort study in 2,316 patients

et al. 2019

View full text Add to dashboard Cite

Purpose: To evaluate the biochemical freedom from failure (bFFF) by risk group and treatment modality and the predictive factors of bFFF by risk group in patients with prostate cancer undergoing permanent seed implantation (PI) with or without external beam radiation therapy (EBRT) in a nationwide prospective cohort study in Japan (J-POPS) during the first 2 years. Methods and Materials: The analyses included 2,316 participants in 42 institutions. bFFF was evaluated using the Phoenix definition and calculated using the Kaplan-Meier method, with factors compared using the Cox proportional hazard model. Results: Median follow-up period was 60.0 months. The 5-year bFFF rates in all patients, 1,028 low-risk, 1,114 intermediate-risk, and 133 high-risk patients were 93.6%, 94.9%, 92.7%, and 91.1%. The 5-year bFFF rates in PI group and EBRT combination therapy group were 93.7% and 93.3%. On multivariate analysis, younger age, higher Gleason score (GS), higher percent positive biopsies (%PB), and lower prostate V100 (p=0.0012, 0.0030, 0.0026, and 0.0368) in all patients; younger age, higher pretreatment PSA, and lower prostate V100 (p=0.0002, 0.0048, and 0.0012) in low-risk; higher GS, higher %PB, and no hormonal treatment (HT) (p=0.0005, 0.0120, and 0.0022) in intermediate-risk; and higher GS and higher %PB (p=0.0329 and 0.0120) in high-risk patients were significantly associated with biochemical failure. Conclusions: PI with or without EBRT resulted in excellent short-term biochemical outcomes in all risk groups, especially in high-risk patients. Age, pretreatment PSA, and prostate V100 in low-risk; GS, %PB, and HT in intermediate-risk; GS and %PB in high-risk patients independently affected bFFF.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In our study, younger age was significantly associated with biochemical failure only in low-risk patients. Some studies have reported the significantly worse biochemical outcomes of PI for younger patients (9,30,31). Others have reported that age was not associated with biochemical failure in low-risk patients (30,32,33,34,35).…”

Section: Discussionmentioning

confidence: 99%